| Health‐related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 trial K Peris, TJ Inocencio, AJ Stratigos, KD Lewis, Z Eroglu, ALS Chang, ... Cancer Medicine 13 (14), e7360, 2024 | | 2024 |
| PPD01. 86 Phase 1 Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced NSCLC BC Cho, GK Dy, TM Kim, D Sarker, O Hamid, SK Williamson, SW Kim, ... Journal of Thoracic Oncology 19 (7), e8-e9, 2024 | | 2024 |
| Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma O Hamid, KD Lewis, A Weise, M McKean, KP Papadopoulos, J Crown, ... Journal of Clinical Oncology, JCO. 23.02172, 2024 | 3 | 2024 |
| A phase 3 trial of fixed dose combinations of fianlimab (anti–LAG-3)+ cemiplimab (anti–PD-1) versus relatlimab+ nivolumab in patients with unresectable or metastatic melanoma. NI Khushalani, J Mani, J Booth, Z Zhang, M Salvati, I Lowy, MG Fury, ... Journal of Clinical Oncology 42 (16_suppl), TPS9611-TPS9611, 2024 | | 2024 |
| A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF‐mutated cancers AP Algazi, J Moon, CD Lao, B Chmielowski, KL Kendra, KD Lewis, ... Cancer 130 (10), 1784-1796, 2024 | | 2024 |
| A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced ccRCC. M Kim, RS McDermott, SK Williamson, BC Cho, A Dowlati, NJ Lakhani, ... Journal of Clinical Oncology 42 (4_suppl), 434-434, 2024 | | 2024 |
| Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors KD Lewis, K Peris, A Sekulic, AJ Stratigos, L Dunn, Z Eroglu, ALS Chang, ... Annals of Oncology 35 (2), 221-228, 2024 | 4 | 2024 |
| Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up AJ Stratigos, A Sekulic, K Peris, O Bechter, S Prey, KD Lewis, ... Journal of the American Academy of Dermatology 90 (2), 414-418, 2024 | 4 | 2024 |
| Health-related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 open-label clinical trial KD Lewis, TJ Inocencio, RGW Quek, PR LaFontaine, Z Eroglu, ... SKIN The Journal of Cutaneous Medicine 8 (1), s337-s337, 2024 | | 2024 |
| Neuro-Oncology Advances AM Menzies, GV Long, A Kohn, H Tawbi, J Weber, K Flaherty, ... | | 2024 |
| POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with … AM Menzies, GV Long, A Kohn, H Tawbi, J Weber, K Flaherty, ... Neuro-oncology advances 6 (1), vdae033, 2024 | | 2024 |
| 43001 Phase 1 study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis O Hamid, A Weise, KD Lewis, TM Kim, M McKean, NJ Lakhani, J Kaczmar, ... Journal of the American Academy of Dermatology 89 (3), AB207, 2023 | | 2023 |
| A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced melanoma: Poor-prognosis subgroup analysis. I Mehmi, KD Lewis, AM Weise, M McKean, KP Papadopoulos, J Crown, ... Journal of Clinical Oncology 41 (16_suppl), 9548-9548, 2023 | 1 | 2023 |
| Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis. O Hamid, KD Lewis, AM Weise, M McKean, KP Papadopoulos, J Crown, ... Journal of Clinical Oncology 41 (16_suppl), 9501-9501, 2023 | 10 | 2023 |
| Targeting MDSC differentiation using ATRA: a phase I/II clinical trial combining pembrolizumab and all-trans retinoic acid for metastatic melanoma RP Tobin, DT Cogswell, VM Cates, DM Davis, JSW Borgers, ... Clinical Cancer Research 29 (7), 1209-1219, 2023 | 29 | 2023 |
| HSR23-097: Health-Related Quality of Life in Patients With Metastatic Basal Cell Carcinoma Treated With Cemiplimab: Analysis of a Phase 2 Open-Label Clinical Trial KD Lewis, TJ Inocencio, RGW Quek, PR LaFontaine, Z Eroglu, ... Journal of the National Comprehensive Cancer Network 21 (3.5), HSR23-097 …, 2023 | | 2023 |
| Primary analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma who progressed on or were intolerant to hedgehog inhibitors KD Lewis, K Peris, A Sekulic, AJ Stratigos, L Dunn, Z Eroglu, ALS Chang, ... SKIN The Journal of Cutaneous Medicine 7 (2), s177-s177, 2023 | | 2023 |
| Phase 1 study of fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis O Hamid, K Lewis, A Weise, M McKean, KP Papadopoulos, J Crown, ... SKIN The Journal of Cutaneous Medicine 7 (2), s179-s179, 2023 | 1 | 2023 |
| Phase 2 study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Long-term follow-up AJ Stratigos, A Sekulic, K Peris, O Bechter, S Prey, M Kaatz, KD Lewis, ... SKIN The Journal of Cutaneous Medicine 7 (2), s178-s178, 2023 | | 2023 |
| Effectiveness of adjuvant pembrolizumab vs high-dose interferon or Ipilimumab for quality-of-life outcomes in patients with resected melanoma: a secondary analysis of the SWOG … JM Unger, A Darke, M Othus, TG Truong, N Khushalani, K Kendra, ... JAMA oncology 9 (2), 251-260, 2023 | 6 | 2023 |
